A number of studies have shown that CHK1 inhibitors or combined with Wee1 (53), R9-capep (54) and other drugs have significant killing effects on MYCN positive NB cell lines, and CHK1 inhibitors can induces regression of preclinical models of human NB (55, 56). However, there are currently no reports on the correlation between CHK1 and the microenvironment of MYCN positive NB. The gene discussed is CHEK1; the disease is neuroblastoma.